Wei Liu - SINOPHARM Insider

SINOPHARM -- Hong Kong Stock  

HKD 34.85  0.85  2.38%

Joint Company Secretary

Dr. Liu Wei serves as a Joint Company Secretary of Sinopharm Group Co. Ltd., since August 24, 2011. He is currently the managing partner of China Group and the managing partner of Beijing Office of DLA Piper. Dr. Liu has PRC lawyer qualification and is a solicitor qualified to practice law in Hong Kong, England and Wales. Dr. Liu graduated from the Northwest University of China, the Chinese University of Political Science and Law, the University of Cambridge, with a bachelor in Chinese literature, a master degree in law, a PhD in Law in 1982, 1986 and 1996 respectively. He also completed his Postgraduate Certificate in Laws of the University of Hong Kong in 2000. Dr. Liu was the first student from the mainland of the PRC to obtain a PhD in law from the University of Cambridge after 1949. Dr. Liu worked for several local and state PRC governmental authorities. He is currently a member of the Shaanxi CPPCC
Age: 57  Executive Since 2011  Ph.D    
86 21 2305 2666  http://www.sinopharmholding.com/En
Liu is currently the managing partner of China Group of DLA Piper and the partner in charge of the PRC affairs and practice. In 1988, Dr. Liu, as one of the lawyers working in Hong Kong in the early stage, participated in related work of the Hong Kong Basic Law, and then he was retained by the Securities and Futures Commission of Hong Kong as a PRC affairs officer responsible for the policies and supervision of law of red chip shares, Hshares and Bshares, and was responsible for coordination with the China Securities Regulatory Commission, the Shenzhen Stock Exchange and the Shanghai Stock Exchange.

Management Efficiency

The company has return on total asset (ROA) of 3.96 % which means that it generated profit of $3.96 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 14.59 % meaning that it generated $14.59 on every $100 dollars invested by stockholders.
The company has accumulated 6.5 B in total debt with debt to equity ratio (D/E) of 90.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SINOPHARM has Current Ratio of 1.23 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Wenhui CaoHealth and Happiness Internatio
N/A
Gui GuoTONG REN TANG
N/A
Jiahua PengHealth and Happiness Internatio
2015
Xiu SongWEIGAO GROUP
N/A
Fangming HuHealth and Happiness Internatio
2014
Hong LiBAIYUNSHAN PH
2017
Miu WongWEIGAO GROUP
N/A
Yuk ChanWEIGAO GROUP
N/A
Jia ChenTONG REN TANG
N/A
Wenyun YangHealth and Happiness Internatio
2010
Yidong WangHealth and Happiness Internatio
2016
Da LiTONG REN TANG
2014
De ZhouWEIGAO GROUP
2009
Li ZhaoHealth and Happiness Internatio
2014
Tak WongHealth and Happiness Internatio
2010
Jianhui PangBAIYUNSHAN PH
2008
De YangTONG REN TANG
N/A
Guangfeng SuBAIYUNSHAN PH
2005
Cun LiuTONG REN TANG
N/A

Entity Summary

Sinopharm Group Co.Ltd., together with its subsidiaries, distributes pharmaceutical and healthcare solutions in the People?s Republic of China. SINOPHARM (1099) is traded on Hong Kong Stock Exchange in Hong Kong. It is located in Sinopharm Group Co., Ltd.Shanghai, and employs 55,869 people.

Did you try this?

Run Portfolio Reporting Now
   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
Hide  View All  Next  Launch Portfolio Reporting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add SINOPHARM to your portfolio

Top Management

SINOPHARM Leadership Team
Jindong Deng, Director
Hailiang Liu, Director
Tze Yu, Director
Fang Yao, Executive
Guangpu Li, President
Yong Liu, VP
Qunbin Wang, Director
Yuhua Li, Director
Bin Zhou, Director
Junyu Guo, President
Lulin She, Chairman
Ping Ma, Director
Wanyong Lian, Executive
Qiyu Chen, Director
Ling Li, Director
Deyong Wen, Director
Zhiming Li, President
Zheng Liu, Director
Fumin Zhuo, Director
Xiuchang Jiang, CFO
Wee Tan, Director
Jun Lu, President
Yulin Wei, President
Chang Lyu, Director
Yijian Wu, Director
Wanjun Ma, President
Guangfu Li, President
Dongjiu Li, Director
Shuangjun Xu, President
Wei Liu, Executive, Ph.D
Zhongxi Cai, President, Ph.D
Qi Chen, Chairman

Stock Performance

SINOPHARM Performance Indicators